Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 1206-1211

  Takeda, Shuso ^a,b   Jiang, Rongrong ^b   Aramaki, Hironori ^a   Imoto, Masumi ^a   Toda, Akihisa ^a   Eyanagi, Reiko ^a   Amamoto, Toshiaki ^c   Yamamoto, Ikuo ^d   Watanabe, Kazuhito ^b  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c NEUES Company Limited   (Japan)

^d KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

15 lipoxygenase; Atherosclerosis; Inhibition; Lipid lipoprotein; Low density lipoprotein; Metabolism. oxidation; Structure activity relationship; 9 Tetrahydrocannabinol; 9 THC 11 oic acid

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CANNABIDIOL 2',6' DIMETHYLETHER; DIMETHYL ETHER; DRONABINOL; NORDIHYDROGUAIARETIC ACID; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; DRUG ISOLATION; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; METABOLITE; NONHUMAN;

EID: 79251544250     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22354     Document Type: Article

References (46)

1. Funk CD. 1996. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1304: 65-84.
2. Brash AR. 1999. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274: 23679-23682.
3. Kuhn H, Thiele BJ. 1999. The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. FEBS Lett 449: 7-11.
4. Kühn H, Belkner J, Zaiss S, Fährenklemper T, Wohlfeil S. 1994. Involvement of 15-lipoxygenase in early stages of atherogenesis. J Exp Med 179: 1903-1911.
5. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. 1995. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 96: 504-510.
6. Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. 2002. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22: 1765-1773.
7. Paoletti R, Gotto Jr AM, Hajjar DP. 2004. Inflammation in Atherosclerosis and Implications for Therapy. Circulation 109: III-20-III-26.
8. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y. 2008. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118: 75-83.
9. Rydberg EK, Krettek A, Ullström C, Ekström K, Svensson PA, Carlsson LM, Jönsson-Rylander AC, Hansson GI, McPheat W, Wiklund O, Ohlsson BG, Hultén LM. 2004. Hypoxia increases LDL oxidation and expression of 15-lipoxygenase-2 in human macrophages. Arterioscler Thromb Vasc Biol 24: 2040- 2045.
10. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. 1999. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103: 1597-1604.
11. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. 2000. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 20: 2100-2105.
12. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786. [Erratum in: Nature. 2005 435:528].
13. Walsh D, Nelson KA, Mahmoud FA. 2003. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11: 137-143.
14. Watanabe K, Narimatsu S, Yamamoto I, Yoshimura H. 1991. Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme. J Biol Chem 266: 2709-2711.
15. 1-terahydrocannabinol. Science 176: 422-424.
16. 9-terahydrocannabinol and related compounds in the mouse. Science 172: 165-167.
17. Wilson RS, Martin BR, Dewey WL. 1979. Some 11-substituted tetrahydrocannabinols. Synthesis and comparison with the potent cannabinoid metabolites 11-hydroxytetrahydrocannabinols. J Med Chem 22: 879-882.
18. 8-tetrahydrocannabinol and its metabolites oxidized at the 11-position. Eur J Pharmacol 63: 1-6.
19. Burstein SB, Hull K, Hunter SA, Latham V. 1988. Cannabinoid and pain responses: a possible role for prostaglandins. FASEB J 2: 3022-3026.
20. Aramaki H, Tomiyasu N, Yoshimura H, Tsukamoto H. 1968. Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull (Tokyo) 16: 822-826.
21. Pitt CG, Fowler MS, Sathe S, Srivastava SC, Williams DL. 1975. Synthesis of metabolites of delta-9-tetrahydrocannabinol. J Am Chem Soc 97: 3798-3802.
22. Gohda H, Narimatsu S, Yamamoto I, Yoshimura H. 1990. In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: On the formation mechanism of cannabielsoin-type metabolite from cannabidiol. Chem Pharm Bull (Tokyo) 38: 1697-1701.
23. Watanabe K, Motoya E, Matsuzawa N, Funahashi T, Kimura T, Matsunaga T, Arizono K, Yamamoto I. 2005. Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206: 471-478.
24. Takeda S, Misawa K, Yamamoto I, Watanabe K. 2008. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Dispos 36: 1917-1921.
25. Takeda S, Usami N, Yamamoto I, Watanabe K. 2009. Cannabidiol-2', 6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. Drug Metab Dispos 37: 1733-1737.
26. Mechoulam R, Ben-Zvi Z, Agurell S, Nilsson IM, Nilsson JL, Edery H, Grunfeld Y. 1973. Delta 6-tetrahydrocannabinol-7-oic acid, a urinary delta 6-THC metabolite: Isolation and synthesis. Experientia 29: 1193-1195.
27. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, Yamada H. 2006. Inhibition of UDP-glucurono- syltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: Dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34: 1277-1282.
28. Razdan RK. 1986. Structure-activity relationships in cannabinoids. Pharmacol Rev 38: 75-149.
29. Johansson E, Norén K, Sjövall J, Halldin MM. 1989. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3: 35-38.
30. Bifulco M, Laezza C, Pisanti S, Gazzerro P. 2006. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148: 123-135.
31. Musshoff F, Madea B. 2006. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 28: 155-163.
32. Brash AR. 1999. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274: 23679- 3682.
33. Kuhn H, Thiele BJ. 1999. The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. FEBS Lett 449: 7-11.
34. Takahashi Y, Yoshimoto T. 2002. What are the functions of mammalian 8-, 12-, and 15-lipoxygenases? Res Adv Cancer 2: 221-229.
35. Ishii Y, Takeda S, Yamada H, Oguri K. 2005. Functional protein-protein interaction of drug metabolizing enzymes. Front Biosci 10: 887-895.
36. Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H. 2005. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol 67: 665-672.
37. Takeda S, Ishii Y, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H. 2005. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: Differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull 28: 2026-2027.
38. Takeda S, Ishii Y, Iwanaga M, Nurrochmad A, Ito Y, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H. 2009. Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: Evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. Mol Pharmacol 75: 956-964.
39. Ishii Y, Takeda S, Yamada H. 2010. Modulation of UDP-glucuronosyltransferase activity by protein-protein association. Drug Metab Rev 42: 140-153.
40. 9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Foren Toxicol 25: 16-21.
41. Gaoni Y, Mechoulam R. 1966. Hashish-VII, The isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 22: 1481-1488.
42. 9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
43. 9-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 245: 141-146.
44. Martínez-Vargas M, Murillo-Rodríguez E, González-Rivera R, Landa A, Méndez-Díaz M, Prospro-García O, Navarro L. 2003. Sleep modulates cannabinoid receptor 1 expression in the pons of rats. Neuroscience 117: 197-201.
45. 8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding. Biol Pharm Bull 21: 408-410.
46. Burstein SH. 1999. The cannabinoid acids: Nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 82: 87-96.